DNA

Brain Cancer Canada Awards an $80,000 research grant to the development of dual function therapies that harness the body’s own immune system to kill brain tumour cells in glioblastomas

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce $80,000 research grant has been awarded…

2 months ago

AI-Based Analysis of Dynamic Digital Radiography Data Gives Researchers Greater Insight into Lung Function and Pulmonary Disorders

KMHA DDR thorax inhale and exhale Images from a DDR acquisition (visualization of anatomy in motion) of a patient breathing,…

2 months ago

Epic Bio to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to…

2 months ago

GeneType and Humanise Health host “Know Your Risk” Event

PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader…

2 months ago

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V:…

2 months ago

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q1 FINANCIAL RESULTS

Greenville, South Carolina, May 23, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based…

2 months ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /…

2 months ago

AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering

         AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering…

2 months ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results…

2 months ago